Pfizer Inc. Rolls Out New Infusion System
Going All Out Against Cancer
Pfizer Inc. (NYSE:PFE) also said that its ‘Ibrance’ drug, when used with another ordinarily-used drug, kept advanced breast cancer in check for longer than the standard treatment alone, in a late stage study. This was as per data released on Wednesday.
Ibrance got a fast U.S. authorization in February 2015 based on its ability to delay disease progress in an earlier, smaller Phase II clinical trial. The condition required was that the results be replicated in a larger study in order to gain full approval . The oral drug has a list price of about $10,300 a month. It has fast gained acceptance with oncologists as an improvement over previous treatments. Some 28,000 women in the U.S. have obtained Ibrance since the fast authorization, Pfizer Inc. (NYSE:PFE) stated.